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Chapter 1 
 
- Background and Aims of the Study Project – 
 
Functional gastrointestinal disorders (FGIDs) include a combination of chronic or recurrent 
gastrointestinal symptoms not explained by known biochemical or structural abnormalities (1).  
FGIDs are multifactorial conditions and several pathophysiological mechanisms appear to contribute 
to their onset.  The most widely accepted pathophysiological hypothesis is the “biopsychosocial 
model” that involves interactions between an altered physiology (e.g., GI motility disturbances, and 
visceral hyperalgesia), and psychosocial factors that, via the gut-brain axis, cause the occurrence of 
GI symptoms in genetic susceptible subjects.  However, the precise pathogenetic mechanism leading 
to the onset of FGIDs has not yet been clarified.  
Due to the lack of specific markers, FGIDs are currently diagnosed according to the Rome 
criteria.  The Rome criteria are intended as a guide for the clinician, since they provide a standardized 
definition and classification for FGIDs.  The first meeting of the paediatric working team was held in 
Rome in 1997, seven years after the publication of the first classification for adult FGIDs, and led to 
the drafting of the first paediatric classification (1); since then, the Rome criteria have been regularly 
updated (2, 3).   
In accordance to the Rome criteria, FGIDs can be divided into two main groups: FGIDs of the 
neonate/toddler, and FGIDs of the child/adolescent (Table 1).  The advantage of using the Rome 
criteria in the clinical practice is that they allow a “positive” approach to the patient, avoiding 
unnecessary tests to rule out an organic cause, with a consequent beneficial effect on both patient's 
health and healthcare costs.  In fact, FGIDs are associated with significant costs: only in the US, from 
1997 to 2009, the number of discharges with a primary diagnosis of FGIDs has risen, and the total 
mean cost per discharge increased from $6.115 to $18.058 (4).  In addition, a recent study from 
Hoekman et al. confirmed that FGIDs, and in particular functional abdominal pain disorders, 
represent a huge economic burden for the society, with an estimated annual cost/patient of €2.512, 
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with half of the costs consisting of inpatient/outpatient healthcare use, and one-fourth of the costs 
related to parental productivity loss (5).   
One of the difficulties in the clinical management of FGIDs is that usually, due to the severity 
and recurrence of the GI symptoms, there is a reluctance of the family to accept a “positive” diagnosis.  
This leads to a continue searching for an organic cause by consulting multiple referrals and looking 
for additional investigations.  This kind of approach is unfavourable, not only in terms of costs, but 
especially for the patient’s perspective.  In fact, it has been demonstrated that the execution of several 
negative clinical tests and non-acceptance of medical reassurance tend to perpetuate the disease in 
the child (6).  
Another problem related to the management of FGIDs is that, in spite of the Rome criteria, 
diagnostic approach to FGIDs still varies widely among different countries, due to several factors, 
including cultural customs.  Currently, in many countries the diagnosis of FGIDs is still considered 
an exclusion diagnosis, inferred after several inappropriate investigations and medical visits, with 
high burden in terms of patient’s anxiety and healthcare costs, due to the abovementioned reasons.  
Over the last years, interest in the study and recognition of FGIDs in children has increased.  
Nevertheless, despite some promising developments, more research is needed to further understand 
the pathophysiology and treatment of these conditions that remain one of the great challenges in 
modern paediatric gastroenterological practice.   
Given these premises, the main aims of the present Ph.D. thesis were: 
1. to evaluate the current diagnostic-therapeutic approach to FGIDs;  
2. to define the prevalence of FGIDs in the Mediterranean part of Europe; 
3. to improve and standardize clinical trials in FGIDs. 
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Table 1. Rome IV classification of Childhood Functional Gastrointestinal Disorders 
 
FUNCTIONAL GASTROINTESTINAL DISORDERS: NEONATE AND TODDLER 
Infant regurgitation 
Infant rumination syndrome 
Cyclic vomiting syndrome 
Infant colic 
Functional diarrhea 
Infant dyschezia 
FUNCTIONAL GASTROINTESTINAL DISORDERS: CHILD AND ADOLESCENT 
Functional nausea and vomiting disorders 
Cyclic vomiting syndrome 
Functional nausea and functional vomiting 
Rumination syndrome 
Aerophagia 
Functional abdominal pain disorders 
Functional dyspepsia 
Irritable bowel syndrome 
Abdominal migraine 
Functional abdominal pain-not otherwise specified 
Functional defecation disorders 
Functional constipation 
Nonretentive faecal incontinence 
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Chapter 2 
 
- The origins of Functional Gastrointestinal Disorders – 
 
 
2.1 Exploring hypotheses and rationale for causes of infantile colic   
 
Infantile colic (IC) is one of the most frequent FGIDs of the neonate/toddler, with an estimated 
prevalence ranging from 5% to 28%, accounting for 10–20% of all the paediatric visits of infants 
aged 2 weeks to 3 months (7).  IC is characterized by paroxysms of irritability and inconsolable crying 
and typically presents in the second or third week after birth, with a peak at 5–8 weeks of age; it 
usually resolves spontaneously by 4 months of age.  Currently, diagnosis of IC is based on the Rome 
IV criteria, that include all of the following, in infants from birth to 5 months of age: a) paroxysms of 
irritability with fussing or crying that start and stop without obvious causes; b) symptoms lasting ≥3 
hours/day and occur ≥3 days a week for at least 1 week; c) no failure to thrive.   
Infantile colic is usually benign and self-limiting, in fact an organic cause for the clinical 
manifestations is found in less than 5% of the infants (8).  Pathogenesis of IC, as most FGIDs, is still 
unclear and has been associated with different factors, such as allergy to cow’s milk proteins, 
alterations in gut hormones and intestinal microflora, behavioral problems (e.g. parental anxiety), 
increasing maternal age, and maternal smoking (9).  It has also been hypothesized that IC represents 
the last stage of the physiological “crying curve” of the development of healthy infants (7).  Taking 
into account all these factors, it is not surprising that actual therapeutic options for IC are non-specific 
and not driven by substantial data. 
Since there is still an unmet clinical need, as current treatments are not efficacious, we decided 
to review the literature on the current management of IC, including nutritional options, prebiotics, 
probiotics, and synbiotics.   
Nutritional Modifications 
The literature regarding nutritional changes in IC management is extensive, with numerous studies 
evaluating the efficacy of hydrolysed formulas in bottle-fed infants, or low-allergen maternal diets in 
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breastfed infants.  Several studies demonstrated an effect of hydrolysate milk on infant distress and 
crying time (10-12).  Nevertheless, for all these studies the level of evidence is low, due to weak 
methods, unclear randomization procedure, incomplete reporting of the data, or unmasked blinding.  
For this reason, the recommendation is to avoid changes in the type of formula, if the child is thriving.  
However, based on clinical reasoning, in a selected subset of formula-fed infants (e.g. children with 
atopy), a trial with a hypoallergenic formula may be an effective treatment for IC (13, 14).  In addition, 
the use of a low-lactose or a high-fibre formula is not supported by evidence of sufficient quality, 
while soy-based formulas are not recommended during the first 6 months of life due to the high 
phytoestrogens content that may affect long- term reproductive health (15) 
Pharmacological Approaches to IC 
Several medications have been proposed for the treatment of IC, such as simethicone, dicyclomine 
hydrochloride, or cimetropium bromide.  However, due to the uncertain efficacy for the management 
of IC, and considering the reported side effects for some of them (e.g. dyspnea, respiratory collapse, 
apnoea, and asphyxia reported for dicyclomine), pharmacological treatment is not recommended for 
the management of colicky infants.  
Behavioral Approaches to IC 
Manipulation of the vertebral column is not recommended, due to the lack of evidence on 
effectiveness and safety (a case of death after manipulation of the cervical and thoracolumbar spine 
is reported).  The level of evidence regarding the effectiveness of increase carrying, reduce 
stimulation of the child, and avoid lifting and patting the baby is low.  
 
In summary, none of the currently available treatments for the management of IC appears to 
be effective, also because of a lack of uniformity in the definitions of IC, primary outcomes and 
instruments used in the different intervention trials.  For this reason, we then decided to examine also 
the evidence available for three hypothetical mechanisms that could be involved in the etiology of 
IC: immaturity of GI motility, immaturity of bile acids absorption with subsequent alteration of 
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absorptive mechanisms, and alterations in the microbiome.  The understanding of these potential 
mechanisms could allow the development of new therapeutic strategies for IC. 
Immaturity of the Intestinal Motility 
Considering the evidence of a transient dysregulation of small intestinal motility, that depends on 
both the extrinsic and enteric neural control, it is possible that immaturity of the enteric nervous 
system during development may cause intestinal hypermotility and contribute to the development of 
IC (16, 17). 
Bile Acid Immaturity 
Several elements of the enterohepatic circulation are altered in the neonate, such as:  
a) levels and composition of the bile in the GI tract and in the serum, with serum concentrations of 
bile acids that increase gradually reaching a peak at 1 month of life, and slowly decrease starting from 
5 months of age (18-20);  
b) immaturity of the alternative pathway of bile acids synthesis, with a higher cholic acid (CA) to 
cheno-deoxycholic acid (CDCA) ratio and a higher glycine/taurine ratio (21).  Interestingly, there is 
a decline in the ratios of CA/CDCA and of glycine/taurine conjugate in most infants within 4–5 
months of age, which corresponds to the timing of resolution of IC; 
c) immaturity in the intestinal absorption of bile salts, with an impairment of the enterohepatic 
circulation that allows the passive absorption of a fraction of bile salts with subsequent loss of part of 
the pool, that may contribute to the steatorrhea and “diarrhea” of the newborn (22, 23); 
d) steatorrhea in the neonatal period, that often occurs during the first month of life (24). 
The presence of steatorrhea and the alterations in bile acids can regulate the composition of the gut 
microbiome (25).  
Alterations of the Gut Microbiome 
It has been demonstrated that colicky infants are more frequently colonized with Clostridium difficile 
during the time of colic than age-matched controls; this difference disappears by the age of 3 months, 
even if stool fatty-acid profiles between the infants who had suffered from severe colic compared to 
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control infants are still different (26).  Moreover, faecal samples of infants with IC have higher counts 
of coliform bacteria and lower counts of lactobacilli compared with children not suffering from colic 
(27, 28).  
 
In conclusion, the immaturity in hepatic synthesis, intraluminal levels, and intestinal 
absorption of bile acids in the neonate could result in malabsorption of fat, with a potential secondary 
effect on the gut microbiome composition.  The alterations in the colonic microbial flora may result 
in an increased nutrient fermentation and reduced levels of dehydroxylated bile acids with a 
subsequent effect on colonic contractile activity (29).  
 
 
 
 
 
 
 
 
 
 
 
 
The results of this review on therapeutic options and new pathogenetic hypotheses for 
IC have been published in Neurogastroenterolgy and Motility in 2017.  
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Chapter 3 
 
Definition and Diagnosis of Functional Gastrointestinal Disorders: the Rome Criteria and the 
Optimization of Clinical Trials 
 
3.1 The Mediterranean-European Area Project on Functional Gastrointestinal Disorders 
 
3.1.1 Functional Gastrointestinal Disorders in Children: A Survey on Clinical Approach in the 
Mediterranean Area 
The Mediterranean-European Area project (MEAP) on FGIDs is a multi-stage project that 
aims to implement international collaboration in the field of FGIDs, to allow a better understanding 
of the epidemiology and of the diagnostic-therapeutic approach to these disorders.  In 2012, 
preliminary data obtained through an informal network, including adult and paediatric 
gastroenterological centers from the Mediterranean area, revealed the following information 
regarding the epidemiology, diagnosis, and treatment of FGIDs: insufficient knowledge of 
epidemiological data on FGIDs; inadequate application of the Rome criteria; and lack of 
standardization in the therapeutic approach to FGIDs, particularly for paediatric patients (30).  Taking 
into account these findings, we decided to launch the first stage of the MEAP: an international 
multicentre prospective survey with the aim of precisely define the diagnostic and therapeutic 
approach to children with suspected FGIDs by general paediatricians from different Mediterranean 
countries.  The coordinator for each country randomly identified, from a national database, a sample 
of general paediatricians fairly distributed across the national territory.  Selected paediatricians were 
contacted by email and were asked to complete 3 questionnaires investigating their approach to 
patients with symptoms suggestive for a FGIDs.  Given the large number of existing FGIDs, we 
decided to focus on 3 of the most prevalent disorders: functional constipation (FC), functional 
regurgitation (FR), and irritable bowel syndrome (IBS).  The questionnaires consisted of 2 different 
sections: the first investigating the use of diagnostic tools (including the Rome criteria), and the 
second evaluating the most used treatment options for FC, FR, and IBS.  
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We collected a total of 278 questionnaires (mean response rate of 25%) from 9 different 
countries: Croatia, Greece, Israel, Italy, Lebanon, Montenegro, Serbia, Slovenia, and Spain.   
Functional Constipation 
Regarding the diagnosis of FC, only 29% of the surveyed paediatricians used the Rome III criteria, 
with 42% of the sample still considering FC as an exclusion diagnosis.  Moreover, 40% of the sample 
declared to perform a rectal examination in each patient with constipation.  In addition, our data show 
a lack of uniformity in the definition of FC, with some paediatricians relying mainly on stool 
consistency, some basing it on bowel frequency, and others on retentive postures or faecal 
incontinence.  A systematic review by Kuizenga-Wessel et al. reported that, in 45 clinical trials, 22 
different definitions of FC were used (31).  This lack of uniformity in the definition of FC jeopardizes 
the results of clinical trials and is reflected in the heterogeneity of definitions reported in clinical 
practice in our study.  Treatment of FC varies between the different countries, with 98% of the 
paediatricians suggesting dietary interventions, mainly increasing fibre and water intake.  However, 
paediatricians should not assume a diet poor in fibre to be the cause of constipation and should be 
aware that the evidence of beneficial increase in dietary fibre or fluids for treating childhood 
constipation is lacking.  In addition, we found that 94% of paediatricians also prescribed medications, 
mainly laxatives. The most used osmotic laxative was polyethyleneglycole, while the most used 
irritative laxative was senna.    
Functional Regurgitation 
Eight percent of the responders based the diagnosis of FR on personal experience, and 31% 
considered FR as an exclusion diagnosis, with only 22% of the sample using Rome III diagnostic 
criteria.  Moreover, it is good to note that 97% based the treatment of FR on parental reassurance, 
77% prescribed thickened feeds, and 70% smaller volume of feeds, in accordance with the North 
American Society for Pediatric Gastroenterology Hepatology and Nutrition-European Society for 
Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for infants with uncomplicated 
recurrent regurgitation that recommend only reassurance, parental education, and modification of 
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feeding composition (32).  However, 21% of the surveyed paediatricians prescribed proton pump 
inhibitors (PPIs) or H2-blockers, and 13% prokinetic agents.  These data is discouraging, since it is 
well known that PPIs are not effective on gastroesophageal reflux disease symptoms in infants (33) 
and that evidence of efficacy and safety of H2-blockers in infants and children is limited and of poor 
quality (34).  Moreover, the prescription of unnecessary therapies in infants with a functional disorder 
is a serious cause of concern, especially considering that PPIs can increase the susceptibility to 
infections (35). 
Irritable Bowel Syndrome 
Considering IBS, 88% of the subjects declared to make a “positive” diagnosis, even if only 26% 
strictly applied the Rome III criteria.  Treatment was mainly focused on the predominant symptom 
(pain, diarrhea or constipation), with analgetics representing the most prescribed treatment for pain, 
and dietary advice the most used suggestion for constipation and diarrhea.  
In conclusion, our data show a wide variability in the diagnostic approach to FGIDs with 
paediatricians frequently relying on personal experience.  The note that <30% of the sample refers to 
the Rome III criteria is disappointing.  Moreover, a large number of paediatricians insists on the 
exclusion of other diagnoses when managing subjects with a suspected FGIDs.  This approach is 
counterproductive since, as abovementioned, one of the advantages of using symptom-based 
diagnostic criteria is to reduce anxiety that drives the families to seek multiple consultations (36).  
Educational efforts are required to ensure a ‘‘positive’’, symptom-based approach to functional 
disorders, avoiding inappropriate use of healthcare resources and excessive treatment of overall 
benign conditions.  In addition, although the Rome criteria and, in general, clinical practice guidelines 
are endorsed by scientific societies and are generally available online, a consistent effort is required 
to increase knowledge and to improve the outcome in patients. 
The results of this survey study on the diagnostic-therapeutic approach to suspected 
FGIDs have been published in Journal of Pediatric Gastroenterology and Nutrition in 2017.  
 25 
 
  
 26 
  
 27 
  
 28 
  
 29 
  
 30 
3.1.2 Functional Gastrointestinal Disorders: Prevalence study in Children and Adolescents in 
the Mediterranean part of Europe 
 
The MEAP is a multi-stage study funded by the European Society for Pediatric Gastroenterology, 
Hepatology, and Nutrition (ESPGHAN), that aims to promote international collaboration in the field 
of FGIDs.  The first stage of the MEAP study has been described in the first section of this chapter 
(Section 3.1.1), and consisted in a survey on the diagnostic and therapeutic approach to children with 
suspected FGIDs by general paediatricians from Mediterranean countries; the second stage’s aim was 
the translation of the standardized Questionnaires on Paediatric Gastrointestinal Symptoms based on 
Rome III Criteria (QPGS-RIII), for non-English speaking patients, in order to assess the prevalence 
of FGIDs in the European Mediterranean Area. 
The prevalence of FGIDs based on Rome III criteria ranges between 12% and 29%.  A study 
from Lewis et al., who recruited 949 mothers of children and adolescents in the US, found an overall 
prevalence of 23.1% based on parental report (37).  Numerous other studies evaluated the 
epidemiology of FGIDs, even if most of them considered only small community samples (38, 39), 
single countries (e.g. Greece, or Norway) (40, 41), or selected age ranges (e.g. adolescents) (42).  
Nevertheless, prevalence of FGIDs in the Mediterranean-European area is poorly defined; for this 
reason, we decided to take advantage of the existing international research network established during 
the first stage of the MEAP to assess the prevalence of FGIDs in a community sample of children and 
adolescents of the Mediterranean-European area.  This school-based, prospective, multicenter study 
represented the third stage of the MEAP, and involved 13,750 children aged 4-18 years from 9 
different countries: Croatia, Greece, Israel, Italy, Jordan, Lebanon, Macedonia, Serbia, and Spain.  
Subjects were enrolled in randomly selected schools distributed throughout the national territory of 
the involved countries, including both large cities and small centers.  The prevalence of FGIDs was 
assessed using the QPGS-RIII, a validated questionnaire specifically designed to diagnose FGIDs in 
children and adolescents (43), translated for non-English speaking countries during the second stage 
of the MEAP. 
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In our study, we have included 6,602 children aged 4-10 years (group A: mean age, 7.7±1.9 
years; girls (F) 50.8%), and 7,148 adolescents aged 11-18 years (group B: mean age, 13.8±2.1 years; 
F, 50.6%).  The mean response rate was 69%.  In children from group A, overall prevalence of FGIDs 
was 20.7% (F 46.5%), with one FGID identified in 17.4% of the subjects, and a combination of two 
FGIDs identified in 2.8%, of three FGIDs in 0.4%, and of four FGIDs in 0.1%.  The most frequent 
disorders were FC (11.7%), IBS (4%), aerophagia (3.5%), and abdominal migraine (AM) (3.1%).  
Focusing on adolescents, we found that overall prevalence of FGIDs was 26.6% (F 55%), with a 
single FGID recorded in 19.5% of the subjects, two FGIDs in 6%, three FGIDs in 1%, and four FGIDs 
in 0.1%.  The most frequent disorders were FC (13.1%), AM (7.8%), aerophagia (6.3%), and IBS 
(5.6%).  Our data are comparable to other studies evaluating the prevalence of all FGIDs according 
to Rome III criteria (37, 38, 40).  However, unlike most of the previous studies, we separated the 
analysis of children (4-10 years) from that of adolescents (11-18 years) to identify age dependent 
differences in the prevalence of FGIDs and, in particular, to obtain information on FGIDs prevalence 
in younger children in whom data is scarce worldwide.  According to our data, prevalence of most 
FGIDs is higher in adolescents compared to children.  In addition, we found that, in subjects aged 11-
18 years, FGIDs were significantly more frequent in girls (M 23.4% vs F 29.1%, P<.001).  Increased 
prevalence of FGIDs in girls is well known, and has been previously described in studies conducted 
in single countries (38, 40, 42).  Finally, we also identified significant differences in the prevalence 
of specific FGIDs among some of the involved countries.  For example, we reported a significantly 
lower prevalence of FC in Croatia and Serbia, a higher prevalence of aerophagia in Croatia, a higher 
prevalence of AM in Israel and Spain (especially in younger children), and a higher prevalence of 
IBS in Israel.  The reasons behind these differences are not completely clear. Nevertheless, since 
FGIDs are considered multifactorial disorders, it can be speculated that they represent the result of a 
variability in the environment, diet, microbiome, and genetic background among the involved 
countries and suggest that the results of single country studies may not be generalized.  
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Our study was the first study evaluating the prevalence of FGIDs in a large sample of children 
and adolescents from Mediterranean countries, confirming that FGIDs are common disorders and that 
their frequency increases with age.  The differences in the prevalence among the involved countries 
suggest a role of environmental and genetic factors in the pathogenesis of FGIDs.  Further studies are 
needed to evaluate the impact of these factors in the onset of FGIDs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results of this international epidemiologic study on the prevalence of FGIDs in the 
Mediterranean-European Area have been accepted for publication in Clinical Gastroenterology 
and Hepatology in 2017.  
 
 33 
 
 
 34 
 
 
 
 
 35 
 
 
 
 36 
 
 
 
 37 
 
 
 
 
 38 
 
 
 
 
 39 
 
 
 
 
 40 
3.2 Functional Chronic Constipation: Rome III Criteria versus Rome IV Criteria 
 
 
Functional constipation is one of the most common FGIDs in children and adolescents, as 
confirmed by data from the MEAP project presented in the previous section of this chapter (Section 
3.1.2).  It is characterized by difficult, painful, and infrequent evacuation of hard stools, with 
symptoms that frequently occur early in life, around 2.3 years (44), and that may have a negative 
impact on quality of life, school performance, and social interactions (45).  
Diagnostic approach to FC is of paramount importance, since a correct diagnosis allows an early 
therapeutic intervention.  Currently, the diagnosis of FC is based on the Rome IV criteria (3), which 
represent the update of the Rome III criteria (2).  In Rome IV criteria minor changes have been made: 
a) in the neonate/toddler group, the age limit for the diagnosis of functional dyschezia has been 
brought up to 9 months, and typical symptoms of infant dyschezia (e.g. straining and crying) have 
been associated also with unsuccessful passage of stools, and not only with successful defecations; 
b) in the child/adolescent group, the duration of symptoms needed to fulfill the criteria for diagnosis 
has been decreased from 2 to 1 month; c) a differentiation between children who are/are not toilet 
trained has been introduced, to help the recognition of faecal incontinence even in toddlers. 
 Taking account of these modifications, we decided to perform a prospective study to evaluate 
the diagnostic agreement between the Rome III and Rome IV criteria, and to estimate the effect on 
prevalence established using the related two questionnaires.  We enrolled 215 children, divided in 2 
age groups: 81 neonates/toddlers aged <4 years (mean age 14.6±7.2 months), and 134 
children/adolescents aged 4-17 years (mean age 111.5±46.3 months).  Our data show that, despite the 
reduction in the symptoms duration, the Rome IV criteria have the same applicability of the Rome III 
criteria for the diagnosis of functional defecation disorders (19% vs 17.6%, respectively; Cohen’s κ 
test agreement κ 0.72).  The prevalence of FC was assessed through the questions on defecation 
frequency (<2 times/week), stool consistency, painful defecation, stool withholding behavior, large 
diameter stools and faecal incontinence.  Prevalence of FC was 17.6% with Rome IV criteria, and 
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19% with Rome III (P=.47).  So, despite the reduction in the symptom duration, we did not miss a 
significant number of diagnoses of FC.  
Considering the neonate/toddler group, we found that 28% reported hard stools, 8% painful 
defecations, 5% large diameter stools, 4% faecal incontinence, and 1% a bowel frequency ≤2 times 
/week, according to both questionnaires.  In the child/adolescent group, 29.8% reported painful 
defecation, 28% faecal incontinence, 8% large diameter stools, and 7% a bowel frequency ≤2 times 
/week, according to both questionnaires.  On the contrary, we found that prevalence of hard stools 
was 19.4% with Rome IV, and 23.1% according to Rome III criteria (P=.1).  Finally, in Rome IV 
criteria a differentiation has been made between children who are toilet trained and children who are 
not.  In accordance with previous literature (46), we found that 30% of children aged 0-4 years had 
acquired toilet training skills (median age 27.6 months).  
 In conclusion, our study highlighted that the new Rome IV criteria have the same applicability 
of the Rome III criteria.  Moreover, we demonstrated that, despite the reduction in the symptom 
duration, the new Rome IV criteria do not fail to diagnose children with FC and that they may improve 
the treatment outcomes because of an earlier diagnosis.  
 
 
 
 
 
 
 
The results of this study have been submitted to The Journal of Paediatrics in 2017.  
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3.3 Development of a core outcome set for clinical trials in childhood constipation: a study 
using a Delphi technique. 
 
The perception of the symptoms of FC is different between the patients, their parents and the 
healthcare professionals (HCPs).  This causes a lack of agreement on the definitions and outcomes in 
therapeutic trials which makes it difficult to pool the results of different studies.  In 2016, Kuizenga-
Wessel et al. assessed the definitions and outcomes in randomized controlled trials conducted in 
children with FC, and confirmed the existence of a heterogeneity in these parameters (31).  In order 
to address this issue, we decided to develop a core outcome set (COS), which is an agreed, 
standardized set of outcomes that guides on the measures that should be reported in a clinical trial.  
In the last few years, several COS were developed for various paediatric conditions, like acute 
diarrhoea, asthma, and infantile colic (47-49); all these studies used the Delphi technique to identify 
important outcomes.  
The use of a COS improves healthcare and increases the capability to evaluate the efficacy of an 
intervention.  However, it is mandatory to include items that matter to the stakeholders.  For this 
reason, in the definition of the COS for FC, we decided to involve not only the HCPs, but also the 
parents and the patients.  In fact, a study from Farrell et al. demonstrated that, when evaluating 
children with FC, the symptoms of concern differ between parents and HCPs (50).   
The study was commissioned by the ESPGHAN, via the Consensus Group on Outcome Measures 
Made in Paediatric Enteral Nutrition Clinical Trials (COMMENT), and was structured in different 
steps.  First, we conducted a survey among HCPs attending two international paediatric 
gastroenterology conferences, asking them to list up to five harmful/beneficial treatment outcomes 
which guided their clinical decision in the management of children with FC, in an inpatient and 
outpatient setting.  The survey was completed by 109 HCPs from 28 different countries.  For infants 
aged 0–1 years, the HCPs reported 89 outcomes for the outpatient setting, and 74 for the inpatient 
setting, while for children aged 1–18 years, they reported 76 outcomes for the outpatient, and 72 
outcomes for the inpatient setting.  Moreover, we collected data from 165 parents of children with 
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FC from 4 different countries (Belgium, Italy, Poland, and The Netherlands), who were asked to list 
up to five treatment outcomes that made them feel their child was managed adequately (comfortable), 
and five treatment outcomes that made them feel their child was managed inadequately 
(uncomfortable).  Concerning children aged 0–1 years, 28 outcomes for the adequate, and 26 for the 
inadequate management were reported, while for subjects aged 1–18 years, 52 outcomes for the 
adequate and 45 for the inadequate management were reported.  Finally, we also included 50 patients 
aged ≥12 years (mean age 14.8 years) who were asked the same questions as their parents, and 
reported 21 outcomes for the adequate and 22 for the inadequate management.  
 In the subsequent step, all the reported outcomes were classified in predefined domains, which 
are subcategories used to group similar outcomes.  All the outcomes mentioned by ≥10% of the 
participants were included in a shortlist.  The shortlists were sent to 80 HCPs who participated in the 
first survey, who were asked to rate the outcomes considering the clinical relevance, and to prioritise 
outcomes by selecting five outcomes they thought to be most important in guiding their clinical 
decision-making; 50/80 (63%) completed the questionnaire. The top 5 outcomes obtained for 
outpatient and inpatient settings were similar, so we combined them into one preliminary outcome 
set per age group.  In addition, a new group of 80 parents and 50 (mean age 13.8 years) patients 
received the shortlists to rank the outcomes, and to prioritise them by selecting the five outcomes that 
made them feel most (un)comfortable.  The outcomes that made the parents and the patients feel 
comfortable and uncomfortable were similar, so we created for each group a single preliminary 
outcome set.  Finally, the five outcomes with the highest rank were selected for each group.  In 
general, stakeholders agreed on the identification of the most important outcomes, even if some 
discrepancies were present.  For example, parents and patients, but not HCPs found “abdominal pain” 
as an important outcome.  In fact, although it is not a characteristic feature of FC, 10%–70% of 
children with FC refer abdominal pain, which can have an impact on quality of life, reducing social 
activities and leading to school absenteeism (51).  Also for “defecation frequency” we found some 
discrepancy, with HCPs considering it one of the most important treatment outcomes, in contrast to 
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parents and patients.  Those preliminary outcome sets for HCPs, parents and patients, were combined 
to create a draft COS that was presented to an expert panel during the COMMENT meeting at the 
ESPGHAN meeting in Athens, Greece (2016), to reach consensus regarding the final COS.   
 
The final COS for children aged 0-18 years included: defecation frequency; stool consistency; 
painful defecation; quality of life of parents and patients; side effects of treatment; faecal 
incontinence, if age appropriate; abdominal pain, if age appropriate; school attendance, if age 
appropriate.  We recommend researchers to use this COS to decrease outcome heterogeneity and 
improve comparability of study results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results of this study have been published in BMJ Open in 2017. 
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Chapter 4 
- Treating Functional Gastrointestinal Disorders - 
 
4.1 Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants 
 
Gastroesophageal reflux (GER) is a condition that occurs frequently in healthy infants, due to 
numerous physiological factors, and tends to resolve spontaneously in 95% of infants within 12 to 14 
months of life (52).  However, in some infants, it can cause a wide spectrum of distressing symptoms, 
such as cough, food refusal, irritability, regurgitation, and vomiting (53). In case of an uncomplicated 
recurrent regurgitation, it is important to recognize physiological GER, which is painless and does 
not affect growth.   
The therapeutic management of GER is mainly based on non-pharmacological interventions (e.g. 
thickened feeds, smaller feeds, and body positioning), while drugs should be prescribed only to 
infants who do not benefit from conservative measures (32).  However, even if most anti-reflux 
medications are associated with severe adverse effects (54), widespread use of empirical therapies in 
infants is still reported (55), as it has been demonstrated in our survey conducted in general 
practitioners from the Mediterranean-European area (56) and in a study conducted by Barron et al. 
which described that, between 1999 and 2004, the prescriptions of PPIs increased by approximately 
800% (57).  This approach reveals a need for harmless, efficacious symptomatic therapies in the 
management of infant GER in the daily practice, to reduce the dramatic increase in PPI prescriptions. 
Previous studies conducted in infants demonstrated that sodium alginate is more effective than 
placebo in reducing the mean frequency and severity of vomiting (58, 59), and that, when associated 
with bicarbonates, it reduces the frequency, height, and acidity of reflux, with the same efficacy as 
acid suppressors, but no systemic effects (60).  Since a new formulation containing magnesium 
alginate was developed (Gastrotuss Baby, DMG Italia SRL, Pomezia, Italy), we decided to perform 
a randomized, open-label, controlled trial to evaluate the efficacy on a GER symptom score of 3 
different treatments: 1) reassurance with lifestyle changes combined and a magnesium (Mg) alginate 
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formulation plus simethicone; 2) reassurance with lifestyle changes and rice-starch thickened 
formula; 3) reassurance with lifestyle changes alone.   
We enrolled 75 consecutive full-term, formula-fed infants (41 boys; median age 5 months; range 
1-10), affected by infant regurgitation, according to the Rome III criteria (61), and no evidence of 
other chronic disease.  Symptoms related to GER were evaluated using the Infant Gastroesophageal 
Reflux Questionnaire (I-GERQ, revised) (62), a validated questionnaire based on the characteristics 
of feeding, regurgitation, crying, bowel habits, stool alteration, weight gain, hiccups, respiratory 
symptoms, family history of GER and allergy, and parental suspicion of GERD.  In case of a score 
>7, the subject was considered as affected by GER (63).  Patients were then randomized to one of the 
3 study groups: group A – consisting of 25 infants treated with reassurance and lifestyle changes + 
Mg alginate plus simethicone; group B – consisting of 25 infants treated with reassurance and lifestyle 
changes + rice-starch thickened non-hydrolysed formula; group C – consisting of 25 infants treated 
with reassurance and lifestyle changes.  Eighty-nine percent of the subjects completed 1 month of 
treatment: patients treated with Mg alginate plus simethicone, and those treated with the thickened 
formula showed a significant reduction of symptoms (P<.005 and P<.02, respectively), with 48% of 
those treated with Mg alginate plus simethicone that were free of symptoms compared to 16% of 
those treated with the thickened formula (P<.03).  Moreover, treatment with Mg alginate plus 
simethicone was more effective on GER symptoms than reassurance alone (P<.0001), while no 
statistical difference was found comparing thickened formula with reassurance alone (P<.1).  Eighty-
five percent of the subjects completed 2 months of treatment: all the 3 groups of patients, irrespective 
of the management, showed a reduction in the symptom score.  However, Mg alginate resulted more 
effective in reducing the symptom scores, with a higher rate of symptom-free patients at both 4 and 
8 weeks. 
 
Our study demonstrated that Mg alginate plus simethicone was more rapid and effective, 
compared to thickened formula, on all the symptoms of GER evaluated, including irritability, 
 70 
respiratory symptoms, vomiting and feeding compliance.  Even if it is well known that GER is a 
benign condition that resolves spontaneously within 12 to 14 months of life, a non-systemic treatment 
can be prescribed to improve symptoms and reduce the distress for infants and their family.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results of this study on the effect of magnesium alginate plus simethicone in the 
management of GER in infants have been published in Journal of Pediatric Gastroenterology 
and Nutrition in 2016.  
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Chapter 5 
 
- Conclusive Remarks – 
 
 
Our studies have confirmed that FGIDs are extremely frequent conditions and that their 
frequency increases with age.  The most frequent disorders in children and adolescents are functional 
constipation, irritable bowel syndrome, abdominal migraine, and aerophagia.  In addition, we have 
found differences in the prevalence of various FGIDs among different countries of the Mediterranean-
European area.  These findings suggest a role of environmental, genetic, and dietetic factors in the 
pathogenesis of FGIDs.  Further studies are needed to evaluate the impact of these factors on the 
onset of FGIDs, in order to allow the development of new therapeutic strategies.  
Moreover, we have demonstrated that, in spite of the availability of the Rome criteria and of 
clinical practice guidelines endorsed by scientific societies, there is still a wide variability in the 
diagnostic approach to FGIDs, with most of the paediatricians still insisting on the exclusion of other 
conditions when managing subjects with FGIDs, with significant impact on healthcare costs and 
patients’ well-being.  
Educational efforts are required to ensure a ‘‘positive’’, symptom-based approach to 
functional disorders, avoiding inappropriate use of healthcare resources and excessive treatment of 
overall benign conditions  
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